340 related articles for article (PubMed ID: 26099996)
1. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
[TBL] [Abstract][Full Text] [Related]
3. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
[TBL] [Abstract][Full Text] [Related]
5. Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients:
Ragia G; Maslarinou A; Atzemian N; Biziota E; Koukaki T; Ioannou C; Balgkouranidou I; Kolios G; Kakolyris S; Xenidis N; Amarantidis K; Manolopoulos VG
Front Pharmacol; 2023; 14():1248898. PubMed ID: 37781702
[No Abstract] [Full Text] [Related]
6. Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population.
Botton MR; Hentschke-Lopes M; Matte U
Ann Hum Genet; 2022 Mar; 86(2):102-107. PubMed ID: 34897655
[TBL] [Abstract][Full Text] [Related]
7. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
[TBL] [Abstract][Full Text] [Related]
8. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
Gentile G; Botticelli A; Lionetto L; Mazzuca F; Simmaco M; Marchetti P; Borro M
Pharmacogenomics J; 2016 Aug; 16(4):320-5. PubMed ID: 26216193
[TBL] [Abstract][Full Text] [Related]
9. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
10. Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.
Riera P; Riba M; Bernal S; Virgili AC; Páez D; Moreno ME
Farm Hosp; 2021 Dec; 45(7):5-10. PubMed ID: 35379107
[TBL] [Abstract][Full Text] [Related]
11. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
12. Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
Miarons M; Manzaneque Gordón A; Riera P; Gutiérrez Nicolás F;
Oncologist; 2023 May; 28(5):e304-e308. PubMed ID: 37014829
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
14. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
[TBL] [Abstract][Full Text] [Related]
15. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.
Hamzic S; Schärer D; Offer SM; Meulendijks D; Nakas C; Diasio RB; Fontana S; Wehrli M; Schürch S; Amstutz U; Largiadèr CR
Br J Clin Pharmacol; 2021 Aug; 87(8):3234-3243. PubMed ID: 33491253
[TBL] [Abstract][Full Text] [Related]
16. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
17. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
[TBL] [Abstract][Full Text] [Related]
19. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
20. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
Falvella FS; Caporale M; Cheli S; Martinetti A; Berenato R; Maggi C; Niger M; Ricchini F; Bossi I; Di Bartolomeo M; Sottotetti E; Bernardi FF; de Braud F; Clementi E; Pietrantonio F
Int J Mol Sci; 2015 Apr; 16(4):8884-95. PubMed ID: 25906475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
